The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

Trials
Carlos ChaccourRegina Rabinovich

Abstract

The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test from nasopharyngeal swab at day 7 post-treatment. The secondary objectives are: 1.To assess the efficacy of ivermectin to reduce the SARS-CoV-2 viral load in the nasopharyngeal swab at day 7 post treatment.2.To assess the efficacy of ivermectin to improve symptom progression in treated patients.3.To assess the proportion of seroconversions in treated patients at day 21.4.To assess the safety of ivermectin at the proposed dose.5.To determine the magnitude of immune response against SARS-CoV-2.6.To assess the early kinetics of immunity against SARS-CoV-2. SAINT is a single centre, double-blind, randomized, placebo-controlled, superiority trial with two parallel arms. Participants will be randomized to receive a single dose of 400 μg/kg ivermectin or placebo, and the number of patients in the treatment and placebo groups will be the same (1:1 ratio). The population for the study will be patients with a positive nasopharyngeal swab PCR test for SARS...Continue Reading

Associated Clinical Trials

Oct 26, 2020·Francisco Luis Ochoa-Jaramillo, MD

Citations

Aug 5, 2020·Psychophysiology·Steven J Luck, Emily S Kappenman
Aug 9, 2020·Psychology & Health·Nahia Idoiaga MondragonAmaia Eiguren Munitis
Sep 26, 2020·Italian Journal of Pediatrics·Elisabetta VenturiniUNKNOWN Italian SITIP-SIP SARS-Cov-2 pediatric infection study group
Feb 9, 2021·Journal of Perinatal Medicine·Amos GrünebaumPhilip A Mackowiak
Oct 11, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fabio Rocha FormigaLindomar Pena
Apr 17, 2021·Frontiers in Immunology·Zena WehbeAli H Eid
Jul 29, 2021·The Cochrane Database of Systematic Reviews·Maria PoppStephanie Weibel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.